scholarly journals Diagnosis of Babesiosis Using an Immunoblot Serologic Test

2001 ◽  
Vol 8 (6) ◽  
pp. 1177-1180 ◽  
Author(s):  
Raymond Ryan ◽  
Peter J. Krause ◽  
Justin Radolf ◽  
Kathy Freeman ◽  
Andrew Spielman ◽  
...  
Keyword(s):  
Human Subjects ◽  
Sodium Dodecyl ◽  
Antibody Test ◽  
Babesia Microti ◽  
Immunoblot Assay ◽  
Granulocytic Ehrlichiosis ◽  
Whole Cell Lysate ◽  
Indirect Immunofluorescent Assay ◽  
History Of ◽  
Human Babesiosis

ABSTRACT Although the current indirect immunofluorescent assay (IFA) diagnostic antibody test for human babesiosis is sensitive and specific, an immunoblot antibody test may be easier to standardize and to perform. Our objective, therefore, was to determine the efficacy of and develop interpretive criteria for an immunoblot antibody test for diagnosing acute human babesiosis using a Babesia microtiwhole-cell lysate as the antigen. We compared the reactivity of sera to a B. microti immunoblot assay in 24 human subjects experiencing symptoms and expressing laboratory evidence of babesiosis, 28 subjects who experienced Lyme disease, 12 subjects who experienced human granulocytic ehrlichiosis, and 51 subjects who reported no history of any of these diseases and whose sera did not react againstB. microti antigen in an IFA test. Immunoblot strips were impregnated with proteins derived from the GI strain of B. microti that had been electrophoresed in an acrylamide sodium dodecyl sulfate gel, followed by electroblotting onto nitrocellulose membranes. The sera of all subjects who experienced babesiosis reacted against the B. microti antigen in the IFA and against at least one of nine immunoblot protein bands specific to B. microti. In contrast, none of the sera from people who appeared not to have experienced this infection reacted against the B. microti antigen in the IFA (compared to 4% in the immunoblot assay). When two reactive bands were considered as definitive, immunoblot test sensitivity was 96%, while specificity was 99% and predictive positivity and predictive negativity were 96 and 99%, respectively. Our B. microti immunoblot procedure shows promise as a sensitive, specific, and reproducible assay for routine clinical diagnosis of acute babesiosis.

scholarly journals Semicentennial of Human Babesiosis, Nantucket Island

Pathogens ◽  
2021 ◽  
Vol 10 (9) ◽  
pp. 1159
Author(s):  
Sam R. Telford ◽  
Heidi K. Goethert ◽  
Timothy J. Lepore
Keyword(s):  
New England ◽  
Index Case ◽  
Babesia Microti ◽  
Case Histories ◽  
Terminal Moraine ◽  
Public Health Burden ◽  
Southern New England ◽  
First Case ◽  
History Of ◽  
Human Babesiosis

Fifty years ago, the index case of human babesiosis due to Babesia microti was diagnosed in a summer resident of Nantucket Island. Human babesiosis, once called “Nantucket fever” due to its seeming restriction to Nantucket and the terminal moraine islands of southern New England, has emerged across the northeastern United States to commonly infect people wherever Lyme disease is endemic. We review the history of babesiosis on Nantucket, analyze its epidemiology and ecology there, provide summaries of the first case histories, and comment on its future public health burden.

scholarly journals Performance Evaluation of a Prototype Architect Antibody Assay forBabesia microti

2018 ◽  
Vol 56 (8) ◽  
Author(s):  
Kevin Cheng ◽  
Kelly E. Coller ◽  
Christopher C. Marohnic ◽  
Zachary A. Pfeiffer ◽  
James R. Fino ◽  
...  
Keyword(s):  
Human Subjects ◽  
Fluorescent Antibody ◽  
Antibody Test ◽  
The United States ◽  
Babesia Microti ◽  
Antibody Testing ◽  
Specific Test ◽  
Content Type ◽  
Therapeutic Drugs ◽  
Prototype Test

ABSTRACTThe tick-borne protozoanBabesia microtiis responsible for more than 200 cases of transfusion-transmitted babesiosis (TTB) infection in the United States that have occurred over the last 30 years. Measures to mitigate the risk of TTB include nucleic acid testing (NAT) andB. microtiantibody testing. A fully automated prototypeB. microtiantibody test was developed on the Architect instrument. The specificity was determined to be 99.98% in volunteer blood donors (n= 28,740) from areas considered to have low endemicity forB. microti. The sensitivity of the prototype test was studied in experimentally infected macaques; a total of 128 samples were detected as positive whereas 125 were detected as positive with an indirect fluorescent antibody (IFA) test; additionally, 83 (89.2%) of the PCR-positive samples were detected in contrast to 81 (87.1%) using an IFA test. All PCR-positive samples that tested negative in the prototype antibody test were preseroconversion period samples. Following seroconversion, periods of intermittent parasitemia occurred; 17 PCR-negative samples drawn in between PCR-positive bleed dates tested positive both by the prototype test (robust reactivity) and IFA test (marginal reactivity) prior to the administration of therapeutic drugs, indicating that the PCR test failed to detect samples from persistently infected macaques. The prototype assay detected 56 of 58 (96.6%) human subjects diagnosed with clinical babesiosis by both PCR and IFA testing. Overall, the prototype anti-Babesiaassay provides a highly sensitive and specific test for the diagnosis ofB. microtiinfection. While PCR is preferred for detection of window-period parasitemia, antibody tests detect infected subjects during periods of low-level parasitemia.

Detection of Kobe-typeBabesia microtiassociated with Japanese human babesiosis in field rodents in central Taiwan and southeastern mainland China

Parasitology ◽  
2008 ◽  
Vol 135 (6) ◽  
pp. 691-699 ◽  
Author(s):  
A. SAITO-ITO ◽  
N. TAKADA ◽  
F. ISHIGURO ◽  
H. FUJITA ◽  
Y. YANO ◽  
...  
Keyword(s):  
Mainland China ◽  
Small Subunit ◽  
Human Infection ◽  
Babesia Microti ◽  
Rrna Gene ◽  
Microscopical Examination ◽  
Small Subunit Rrna ◽  
Central Taiwan ◽  
Field Rodents ◽  
Human Babesiosis

SUMMARYField rodent surveys forBabesiainfection were performed from 2002 to 2005 in the vicinities of human babesiosis occurrences in Taiwan and mainland China.Babesia microtiwas identified by microscopical examination and/or PCR in 1Rattus coxingaand 1Crocidura horsfieldiiin central Taiwan and in 13Niviventer confucianusand 1Apodemus agrariusin Zhejiang and Fujian Provinces of southeastern China. Of 15B. microtisamples detected by PCR, all except 1 were shown to be the Kobe-type, the aetiological small subunit rRNA gene-type of the first Japanese patient; the exception was also a Kobe-related type. The Kobe-type had been found in rodents only in a few places including the human infection occurrence place in Japan. The internal transcribed spacer 1 to 2 sequences of the Taiwanese and Chinese Kobe-types were very similar to each other but considerably different (approx. 94% pairwise identities) from that of the Japanese Kobe-type. A Taiwanese Kobe-type strain was serologically differentiated from the Kobe strain originating from the Japanese first patient. The distribution of the Kobe-type in the vicinities of human babesiosis occurrences in Taiwan and China as well as in Japan is suggestive of involvement of the Kobe-type in Asian human babesiosis.

scholarly journals Electrodermal Response in Gaming

2011 ◽  
Vol 2011 ◽  
pp. 1-14 ◽  
Author(s):  
J. Christopher Westland
Keyword(s):  
Computer Games ◽  
Emotional Response ◽  
Human Subjects ◽  
Skin Resistance ◽  
The Body ◽  
Electrodermal Response ◽  
Factors Affecting ◽  
Measuring Devices ◽  
History Of ◽  
Body Resistance

Steady improvements in technologies that measure human emotional response offer new possibilities for making computer games more immersive. This paper reviews the history of designs a particular branch of affective technologies that acquire electrodermal response readings from human subjects. Electrodermal response meters have gone through continual improvements to better measure these nervous responses, but still fall short of the capabilities of today's technology. Electrodermal response traditionally have been labor intensive. Protocols and transcription of subject responses were recorded on separate documents, forcing constant shifts of attention between scripts, electrodermal measuring devices and of observations and subject responses. These problems can be resolved by collecting more information and integrating it in a computer interface that is, by adding relevant sensors in addition to the basic electrodermal resistance reading to untangle (1) body resistance; (2) skin resistance; (3) grip movements; other (4) factors affecting the neural processing for regulation of the body. A device that solves these problems is presented and discussed. It is argued that the electrodermal response datastreams can be enriched through the use of added sensors and a digital acquisition and processing of information, which should further experimentation and use of the technology.

scholarly journals The Global Emergence of Human Babesiosis

Pathogens ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 1447
Author(s):  
Abhinav Kumar ◽  
Jane O'Bryan ◽  
Peter J. Krause
Keyword(s):  
United States ◽  
Wide Spectrum ◽  
The United States ◽  
Ixodid Ticks ◽  
Babesia Microti ◽  
Babesia Species ◽  
Human Pathogens ◽  
Endemic Disease ◽  
Predominant Species ◽  
Human Babesiosis

Babesiosis is an emerging tick-borne disease caused by intraerythrocytic protozoa that are primarily transmitted by hard-bodied (Ixodid) ticks and rarely through blood transfusion, perinatally, and organ transplantation. More than 100 Babesia species infect a wide spectrum of wild and domestic animals worldwide and six have been identified as human pathogens. Babesia microti is the predominant species that infects humans, is found throughout the world, and causes endemic disease in the United States and China. Babesia venatorum and Babesia crassa-like agent also cause endemic disease in China. Babesia divergens is the predominant species in Europe where fulminant cases have been reported sporadically. The number of B. microti infections has been increasing globally in recent decades. In the United States, more than 2000 cases are reported each year, although the actual number is thought to be much higher. In this review of the epidemiology of human babesiosis, we discuss epidemiologic tools used to monitor disease location and frequency; demographics and modes of transmission; the location of human babesiosis; the causative Babesia species in the Americas, Europe, Asia, Africa, and Australia; the primary clinical characteristics associated with each of these infections; and the increasing global health burden of this disease.

scholarly journals Human Babesiosis in Europe

Pathogens ◽  
2021 ◽  
Vol 10 (9) ◽  
pp. 1165
Author(s):  
Anke Hildebrandt ◽  
Annetta Zintl ◽  
Estrella Montero ◽  
Klaus-Peter Hunfeld ◽  
Jeremy Gray
Keyword(s):  
Clinical Management ◽  
Diagnostic Tools ◽  
Genetic Characteristics ◽  
Susceptibility To Infection ◽  
First Case ◽  
The Usa ◽  
Life Threatening ◽  
History Of ◽  
Etiological Agents ◽  
Human Babesiosis

Babesiosis is attracting increasing attention as a worldwide emerging zoonosis. The first case of human babesiosis in Europe was described in the late 1950s and since then more than 60 cases have been reported in Europe. While the disease is relatively rare in Europe, it is significant because the majority of cases present as life-threatening fulminant infections, mainly in immunocompromised patients. Although appearing clinically similar to human babesiosis elsewhere, particularly in the USA, most European forms of the disease are distinct entities, especially concerning epidemiology, human susceptibility to infection and clinical management. This paper describes the history of the disease and reviews all published cases that have occurred in Europe with regard to the identity and genetic characteristics of the etiological agents, pathogenesis, aspects of epidemiology including the eco-epidemiology of the vectors, the clinical courses of infection, diagnostic tools and clinical management and treatment.

scholarly journals Evaluation of the fluorescent gonococcal test-heated

1976 ◽  
Vol 4 (5) ◽  
pp. 423-428
Author(s):  
H A Gaafar
Keyword(s):  
Indirect Fluorescent Antibody Test ◽  
Fluorescent Antibody ◽  
Clinical Signs ◽  
Antibody Test ◽  
Signs And Symptoms ◽  
Risk Groups ◽  
Indirect Fluorescent Antibody ◽  
Culture History ◽  
History Of ◽  
Clinical Signs And Symptoms

In a 1-year evaluation of the indirect fluorescent antibody test for gonorrhea, 16,127 specimens from low-and high-risk groups were examined, and the results were compared with culture, history of exposure to a known patient, and clinical signs and symptoms. The results confirmed the usefulness of the indirect fluorescent antibody test for gonorrhea as a screening procedure, especially for women in the low-risk group. The test is more economic and probably more sensitive than culture for mass screening of asymptomatic women.

scholarly journals Technologies for Detection of Babesia microti: Advances and Challenges

Pathogens ◽  
2021 ◽  
Vol 10 (12) ◽  
pp. 1563
Author(s):  
Scott Meredith ◽  
Miranda Oakley ◽  
Sanjai Kumar
Keyword(s):  
United States ◽  
Early Stage ◽  
Parasite Burden ◽  
The United States ◽  
Babesia Microti ◽  
Current Status ◽  
Low Grade ◽  
Babesia Species ◽  
Technological Advances ◽  
Human Babesiosis

The biology of intraerythrocytic Babesia parasites presents unique challenges for the diagnosis of human babesiosis. Antibody-based assays are highly sensitive but fail to detect early stage Babesia infections prior to seroconversion (window period) and cannot distinguish between an active infection and a previously resolved infection. On the other hand, nucleic acid-based tests (NAT) may lack the sensitivity to detect window cases when parasite burden is below detection limits and asymptomatic low-grade infections. Recent technological advances have improved the sensitivity, specificity and high throughput of NAT and the antibody-based detection of Babesia. Some of these advances include genomics approaches for the identification of novel high-copy-number targets for NAT and immunodominant antigens for superior antigen and antibody-based assays for Babesia. Future advances would also rely on next generation sequencing and CRISPR technology to improve Babesia detection. This review article will discuss the historical perspective and current status of technologies for the detection of Babesia microti, the most common Babesia species causing human babesiosis in the United States, and their implications for early diagnosis of acute babesiosis, blood safety and surveillance studies to monitor areas of expansion and emergence and spread of Babesia species and their genetic variants in the United States and globally.

Sign in / Sign up

Export Citation Format

Share Document